40 results about "Neoplasm" patented technology

This disclosure relates to a method for detecting colorectal cancer. The method comprises determining whether an advanced neoplasm is present in a first screening time period and upon determining that an advanced neoplasm is present in the first screening time period, performing colonoscopy in a second screening time period, after the first screening time period, to detect colorectal cancer. There is further provided a method for stratification of a subject comprising upon detection of an advanced neoplasm in a first screening time period, stratifying the subject into a high risk stratification for developing colorectal cancer in a second screening time period. There is further provided a computer implemented method for calculating a risk score for developing colorectal cancer comprising determining patient data; applying a trained machine learning model to the patient data to determine the risk score; and outputting the risk score.

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases in a subject, wherein the proliferative diseases include cancer, benign neoplasm, angiogenesis, inflammatory disease, autoinflammatory disease, and autoimmune disease, and the cancer includes leukemia, melanoma, multiple myeloma. Treatment of a subject having a proliferative disease with the compounds or compositions of the present invention can inhibit abnormal activity of cyclin-dependent kinase 7, thus inducing apoptosis and / or inhibiting transcription in the subject.

Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general.

Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and / or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.

The present disclosure relates to the use of compound (I) and any of its salts for the treatment of a neoplasm characterized by high expression of toll-like receptor 4 (TLR4) in the tumor or its microenvironment, associated with at least one of the pathophysiological complications including immunosuppression, angiogenesis, fibrosis, or metastasis.

The present invention relates to systems and methods for classification of cancer from gene expression input data. The method including: receiving a training dataset including nucleic acid data points from one or more samples; identifying classes in the training dataset including performing recursive clustering by, at each successive iteration, performing a search to identify clusters based on similarity, wherein each class of the classes is associated with a tumor; training a machine learning model to associate the nucleic acid data points of the training dataset with the identified classes; receiving the gene expression input data for classification; classifying, using the trained machine learning model, the gene expression input data as one or more of the identified classes; and outputting the classification of the gene expression input data.

The present disclosure provides a method for the treatment of neoplastic disease in a mammalian subject the method comprising the administration of an IL-10 agent in combination with the administration of at least one modulator of at least one immune checkpoint pathway. The present disclosure further provides a method for the treatment of neoplastic disease wherein the neoplasm has a low or intermediate tumor mutation burden, low or intermediate level of expression of the immune checkpoint molecule, or metastatic neoplastic disease.

Disclosed are methods of treatment, compositions and kits comprising endocannabinoid receptor (ECR) antagonist and an mTOR inhibitor for treating neoplasm in a subject in need thereof, and reducing drug resistance to standard treatment.

The present invention relates to novel and stable preparations of bacterial extracts that exhibit considerably greater stability over time, to new methods of preparing them, to pharmaceutical formulations based on these new stabilized bacterial extracts, as well as to new routes of administration and delivery devices for the treatment and / or prevention of acute and chronic immunological disorders resulting from infections, inflammation, neoplasms, or dysbiosis.

Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as gastric cancer.

The invention relates to cannabidiol-based (CBD) formulations, and to their use in treating, preventing or alleviating pain, inflammation, an autoimmune disease, a neurological disease, neoplasm, or nausea in a subject. The invention also concerns low-dose CBD compositions, and extends to their use in methods of treatment.

The present disclosure provides T cell receptors (TCRs) that bind to COL6A3 and their use in medical treatment or prophylaxis, for example the treatment of COL6A3-expressing neoplasms or cancers. The present disclosure also provides nucleic acids and expression vectors that encode the TCRs.

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopologues, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and / or preventing diseases (e.g., proliferative diseases (e.g., cancers and benign neoplasms), inflammatory diseases (e.g., rheumatoid arthritis), and vascular diseases (e.g., atherosclerosis) in a subject. Provided are methods of inhibiting a INK (e.g., JNK1, JNK2, or JNK3) in a subject.

The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and / or preventing e.g. autoimmune, immunological, rheumatology, vascular disorders, ophthalmologic disorders, fibrotic disorders, metabolic and gastrointestinal disorders, neuroinflammatory and neurodegenerative diseases, neoplasms and cancer associated disorders, hormone related diseases and immunological disorders resulting from viral and bacterial infectious diseases and complications thereof. wherein R 1 is COOR 4, (CH 2 ) n COOR 4, SO 3 H, (CH 2 ) n SO 3 H or CONH-R 10; one of R 2 and R 3 is H and the other is R 5.

Disclosed are compositions comprising delta-tocotrienol and methods for using the same in the prevention of cancer progression. The methods comprise of reducing, inhibiting, decreasing, and / or preventing the progression of a neoplasm to a cancer (including, but not limited to lung cancer, ovarian cancer, breast cancer, rectal cancer, pancreatic, colon cancer, or intraductal papillary mucinous neoplasm (IPMN) to pancreatic ductal adenocarcinoma) in a subject comprising administering to a subject a therapeutically effective amount of a composition comprising delta-tocotrienol (d-T3).

The skin benign neoplasm removing device for the dermatology department comprises a bracket and a removing assembly, the removing assembly comprises a rotating seat rotationally connected with one side of the bracket, an orientation rod and a pair of clamping rods are arranged on the rotating seat, an end plate is slidably clamped between the two clamping rods, and the two ends of the end plate are connected with a fixing seat and an orientation block correspondingly; the orienting rod penetrates through the inner side of the orienting block; a connecting cylinder is arranged at the top end of the fixed seat; the removing assembly can remove benign skin neoplasm on the skin surface of a patient, the device combines the functions of cutting and scraping the neoplasm, and compared with mainstream laser treatment, physical scraping treatment cannot cause heat damage to peripheral tissues, so that compared with laser treatment, the physical scraping treatment has the advantages that the treatment efficiency is greatly improved, and the treatment cost is reduced. And the probability of scars left after complete healing is lower, so that the removal effect of the device is improved.

Described are devices, systems, and methods for controlled delivery of therapeutic and / or diagnostic agent(s) in a tissue in a subject. In particular, provided are carrier devices in which the agent(s) may be enclosed. One or more carrier devices may be injected or implanted at target loci in a tissue, such as in a malignant neoplasm. The agent(s) may diffuse from the carrier devices in a predetermined and controlled manner. Further provided are methods for developing optimized parameters for intraparenchymal placement of carrier devices and diffusion of the agent(s), to achieve an optimized therapeutic exposure in the target tissue. Further provided are devices and systems for intraparenchymally placing carrier devices at desired loci in a tissue.

Processes and materials to detect neoplasms from a biopsy are described. Processes and materials to build a sequencing library are described. Processes and material to perform targeted sequencing are described. Processes and materials to mitigate confounding sources are described. Cell-free nucleic acids can be sequenced and the sequencing result can be utilized to detect sequences derived from a neoplasm.

Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and / or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.

The present invention relates to the dosage and administration of anti-BCMA agents for the treatment of BCMA positive neoplasms. More specifically, the present invention relates to an antibody construct comprising a first domain which binds to BCMA, a second domain which binds to CD3 and a third domain which extends or enhances the half-life of the antibody construct, for use in the treatment or amelioration of a BCMA positive neoplasm, wherein the antibody construct is administered at a specified dose in at least one cycle. Moreover, the invention relates to a method for the treatment of a BCMA positive neoplasm comprising administering a specified dose of such antibody construct, and the use of such antibody construct for the manufacture of a medicament for the treatment of a BCMA positive neoplasm.

Methods to identify modulators of histone acetyltransferases are described. Modulators of histone acetyltransferases can be used to treat individuals. In some instances, modulators of histone acetyltransferases are utilized to treat individuals having a neoplasm.

Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer.

The present invention relates to a pharmaceutical composition for use in the treatment or prophylaxis of mammary / breast carcinomas, in particular locally recurring or metastasizing mammary carcinomas in a patient or group of patients, who has or is suspected of having a breast carcinoma, comprising at least 4 to 8 HLA-A tumor antigen peptides corresponding to MHC class I complexes and at least 2 tumor antigen peptides corresponding to MHC class II complexes, wherein the HLA tumor antigen peptides are tumor-exclusive or tumor-associated HLA antigen peptides and are directed against at least one MHC complex including combinations thereof; a pharmaceutical composition, a kit (or parts thereof); a method for determining an HLA peptide of class I and / or II; a method for preparing a pharmaceutical composition according to the invention; and the use of a pharmaceutical composition according to the invention for the preparation of a pharmaceutical composition for the treatment of malignancies, leukemias and neoplasms.

The present invention relates to the field of biotechnology, medicine, in particular, oncology and pharmaceuticals, and is directed to ready-to-use dosage forms of a medicinal product for combination gene-directed enzyme prodrug therapy—immune therapy of human solid malignant neoplasms.Two variants of two-component dosage forms of the medicinal product are proposed. In the first variant, the composition of the medicinal product includes the first and second containers, the first container containing the first component containing the pCMV-HSVtk-hGM-CSF therapeutic plasmid DNA in a therapeutically effective amount in the form of a frozen aqueous solution, and the second container containing the second component containing the polyethyleneimine-polyethylene glycol-TAT peptide block copolymer in a therapeutically effective amount in the form of a frozen aqueous solution. A ready-to-use solution for injection, intended for administration to a patient, is prepared ex tempore by thawing the referenced two components and mixing them.In the second variant, the composition of the medicinal product includes the first and second containers, the first container containing the first component containing the pCMV-HSVtk-hGM-CSF therapeutic plasmid DNA in a therapeutically effective amount in the form of a lyophilisate, and the second container containing the second component containing the polyethyleneimine-polyethylene glycol-TAT peptide block copolymer in a therapeutically effective amount in the form of a frozen aqueous solution. A ready-to-use solution for injection intended for administration to a patient is prepared ex tempore by reconstituting the first component by adding water, thawing the second component and mixing them.The proposed dosage forms can be used for the treatment of human solid malignant neoplasms. The two proposed dosage forms demonstrate high stability and retain their therapeutic efficacy for at least 18 months.

Disclosed herein is a glycoengineered tumor cell or a glycoengineered tumor cell fragment for use in treatment and / or prevention of cancer, in particular cancerous neoplasms, in a subject. The glycoengineered tumor cell or tumor cell fragment includes a tumor cell surface including one or more carbohydrate antigen moieties. Furthermore, a pharmaceutical composition including such a cell or cell fragment, a method for producing such a glycoengineered tumor cell or tumor cell fragment and a method of treatment of a subject including the administration of such a glycoengineered tumor cell or glycoengineered tumor cell fragment to a subject is disclosed.

The present invention relates to a pharmaceutical composition useful for preventing or treating malignant tumors and, to a composition for preventing or treating malignant neoplasm, comprising, as an active ingredient, at least one selected from the group consisting of a compound represented by chemical formula (1), a pharmaceutically acceptable salt, a hydrate, a solvate, and a prodrug of the compound, and a combination thereof.

The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.

The present invention provides novel compounds of Formula (I), (II), or (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and / or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK7, CDK12, or CDK13), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject.